LGND · Ligand Pharmaceuticals Inc
United States · RS rating 89 · As of 2026-11-03
| Price | 313.52 USD |
|---|---|
| 1-day change | +2.1% |
| RS rating (overall / 1M / 3M / 12M) | 89 / 64 / 74 / 89 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 51 / 76 / 45 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -62.7% |
| Sales growth Q/Q | -48.3% |
| Distance from 52-week high | +2.9% |
| Market cap (USD) | $4.6B |